NASDAQ
NIVF
Last Price
US $0.5498
KEY FIGURES
MKT CAP
$104.2K
EPS
TTM
$46.69
EPS Growth (1Y)
-175.32%
PEG
TTM
-
P/E
TTM
0.01x
P/S
TTM
0.04x
YIELD
-
GROWTH (5Y CAGR)
Revenue
-
EBITDA
-
Cash flow
Cash Flow (DCF)
Fair Value
Market $0.5498
—
Default assumptions
EBITDA Multiple
Fair Value
Market $0.5498
22877.45%
Default assumptions
Valuation
Financial
Performance
Cash flow to debt coverage
NewGenIvf Group Limited cash flow to debt ratio of -224.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
NewGenIvf Group Limited's free cash flow has decreased 100.50% from $-8.32M last year to $-16.68M, signaling decreasing performance
Debt-to-equity ratio
NewGenIvf Group Limited's debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
NewGenIvf Group Limited's debt has increased relative to shareholder equity from -2.89 last year to 0.18 today, signaling weakened financials
Net debt to EBITDA
NewGenIvf Group Limited has a net debt to EBITDA ratio of 0.38x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Interest coverage
NewGenIvf Group Limited's interest coverage ratio is -15.25, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
NewGenIvf Group Limited's profit margin has increased (-3.60K%) in the last year from -9.66% to 338.20%, signaling increasing performance
Current ratio
NewGenIvf Group Limited's short-term assets of $7.38M exceed its short-term liabilities of $2.37M
Return on assets
NewGenIvf Group Limited's return on assets of 27.98% is higher than the 5.00% threshold, indicating efficient asset utilization
Return on equity
NewGenIvf Group Limited's return on equity of 32.69%, is higher than 15.00%, indicating good performance
Earnings quality
NewGenIvf Group Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
NewGenIvf Group Limited has insufficient public price history to evaluate earnings stability.
Positive free cash flow
NewGenIvf Group Limited has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
NewGenIvf Group Limited has negative free cash flow, indicating cash burn
Earnings growth
NewGenIvf Group Limited's yearly earnings has increased -1.98K% since last year from $-525.00K to $9.88M, signaling increasing performance
Revenue growth
NewGenIvf Group Limited's yearly revenue has decreased 13.01% since last year from $5.43M to $4.73M, signaling decreasing performance
Return on invested capital
ROIC -24.27% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
NewGenIvf Group Limited's 3-year revenue CAGR of -7.36% is negative, indicating declining revenue over the past 3 years
Revenue consistency
NewGenIvf Group Limited had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance
Return on equity consistency
NewGenIvf Group Limited has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
NewGenIvf Group Limited has insufficient data to evaluate this check.
Earnings yield (TTM)
NewGenIvf Group Limited has an earnings yield of 7.67K%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
NewGenIvf Group Limited is undervalued relative to its fair value price of 126.33 based on EBITDA multiple model
EV/EBITDA (FY)
NewGenIvf Group Limited has an EV/EBITDA ratio of 0.39x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
PEG ratio (TTM/FY)
NewGenIvf Group Limited has insufficient diluted EPS history to calculate the PEG ratio.
Price-to-book ratio (FY)
NewGenIvf Group Limited has a price-to-book ratio of 0.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
NewGenIvf Group Limited has a price-to-sales ratio of 0.04x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
32.69%
Return on equity
ROIC: -24.27%
Valuation History
0.01X
Price to Earnings
EV/EBITDA: 0.44X
Cash flow
Profit margin
-
EARNINGS FV (GRAHAM)
Fair Value
Market $0.5498
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.